Advertisement
Table 1 Clinical characteristic according to PI3KCA mutation status
| NN | First hepatectomy | Second hepatectomy | Third hepatectomy | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Mutation | Mutation | No Mutation | Mutation | No Mutation | Mutation | |||||||||
| N = 8 | N = 5 | N = 11 | N = 6 | N = 2 | N = 2 | |||||||||
| Hepatic metastases | ||||||||||||||
| Mean age at resection + SD Years | 42 + 7 | 44 + 7 | 51 + 11 | 50 + 12 | 63 + 18 | 42 + 4 | ||||||||
| Mean interval between primary removal and liver resection + SD Months | 42 + 20 | 47 + 37 | 43 + 21 | 46 + 33 | 28 + 9 | 22 + 9 | ||||||||
| Mean number of BCLM diagnosed + SD Distribution | 2 + 2 | 2 + 2 | 2 + 2 | 2 + 1 | ||||||||||
| Unilateral | 5 | 50% | 4 | 80% | 9 | 82% | 4 | 67% | 1 | 50% | 1 | 100% | ||
| Bilateral | 5 | 50% | 1 | 20% | 2 | 18% | 2 | 33% | 1 | 50% | 0 | 0% | ||
| Concomitant extra-hepatic disease | ||||||||||||||
| No | 10 | 91% | 4 | 80% | 8 | 73% | 4 | 67% | 1 | 50% | 1 | 100% | ||
| Yes | 1 | 9% | 1 | 20% | 3 | 27% | 2 | 33% | 1 | 50% | 0 | 0% | ||
| Chemotherapy before liver resection | ||||||||||||||
| No | 2 | 18% | 1 | 20% | 0 | 0% | 1 | 17% | 0 | 0% | 0 | 0% | ||
| Yes | 9 | 82% | 4 | 80% | 11 | 100% | 5 | 83% | 2 | 100% | 2 | 100% | ||
| Hormonal Therapy before liver resection | ||||||||||||||
| No | 8 | 73% | 2 | 40% | 2 | 18% | 2 | 33% | 1 | 50% | 0 | 0% | ||
| Yes | 3 | 27% | 3 | 60% | 9 | 82% | 4 | 67% | 1 | 50% | 2 | 100% | ||
| Targeted Therapy before liver resection | ** | |||||||||||||
| No | 7 | 64% | 4 | 80% | 2 | 18% | 5 | 83% | 1 | 50% | 2 | 100% | ||
| Yes | 4 | 36% | 1 | 20% | 9 | 82% | 1 | 17% | 1 | 50% | 0 | 0% | ||
| Histopathological characteristics | ||||||||||||||
| Mean maximum resected tumor size + SD, mm | 17 + 15 | 33 + 15 | * | 21 + 16 | 26 + 12 | 19 + 8 | 23 + 11 | |||||||
| Resection margin*** | ||||||||||||||
| R0 | 8 | 89% | 3 | 60% | 8 | 80% | 4 | 67% | 0 | 0% | 2 | 100% | ||
| R1 | 1 | 11% | 2 | 40% | 2 | 20% | 2 | 33% | 1 | 100% | 0 | 0% | ||
| Microscopic intrahepatic invasion | ||||||||||||||
| No | 6 | 60% | 1 | 20% | 7 | 64% | 2 | 33% | – | 0 | 0% | |||
| Yes | 4 | 40% | 4 | 80% | 4 | 36% | 4 | 67% | – | 2 | ||||
| Cell surface receptors status | ||||||||||||||
| Estrogen | ||||||||||||||
| Negative | 0 | 0% | 2 | 40% | 4 | 36% | 2 | 33% | 0 | 0% | 1 | 50% | ||
| Positive | 8 | 100% | 3 | 60% | 7 | 64% | 4 | 67% | 2 | 100% | 1 | 50% | ||
| Progesterone | ||||||||||||||
| Negative | 5 | 63% | 4 | 80% | 6 | 55% | 2 | 33% | 1 | 50% | 1 | 50% | ||
| Positive | 3 | 38% | 1 | 20% | 5 | 45% | 4 | 67% | 1 | 50% | 1 | 50% | ||
| Her2/Neu | ||||||||||||||
| Negative | 6 | 75% | 4 | 80% | 6 | 60% | 4 | 67% | 0 | 0% | 2 | 100% | ||
| Positive | 2 | 25% | 1 | 20% | 4 | 40% | 2 | 33% | 1 | 100% | 0 | 0% | ||
| Differentiation | ||||||||||||||
| Well differentiated | 0 | 0% | 1 | 20% | 1 | 14% | 2 | 40% | 1 | 50% | 0 | 0% | ||
| Moderately differentiated | 5 | 71% | 4 | 80% | 3 | 43% | 2 | 40% | 0 | 0% | 1 | 50% | ||
| Poorly differentiated | 2 | 29% | 0 | 0% | 3 | 43% | 1 | 20% | 1 | 50% | 1 | 50% | ||
